Back to results
US 2013/0274469 A1Published application
Isoxazolo-pyridine derivatives
AssigneeHoffmann-La Roche Inc.
InventorsBernd Buettelmann, Roland Jakob-Roetne, Henner Knust, Matthew C. Lucas, Andrew Thomas
Life of this patent
Estimating the term…
Abstract
The present invention is concerned with isoxazole-pyridine derivatives of formula I wherein X, R1 to R6 are as described herein. The compounds are active on the GABA A α5 receptor binding site and useful for the treatment of cognitive disorders, such as Alzheimer's disease.
Claims30
A compound of formula I
- wherein
- X is O or NH;
- R1 is phenyl, optionally substituted with 1, 2 or 3 halo,
- R2 is H or CH3 or CF3;
- R3, R4, R5, and R6 are H;
- C1-7alkyl, optionally substituted with one or more halo, cyano, or hydroxy,
- C1-7alkoxy, optionally substituted with one or more halo,
- CN,
- halo,
- NO2,
- S—C1-7alkyl,
- S(O)—C1-7alkyl
- benzyloxy, optionally substituted with one or more E,
- —C(O)—Ra, wherein Ra is hydroxy, C1-7alkoxy, C1-7alkyl, phenoxy or phenyl,
- 3- to 7-membered heterocyclyl, optionally substituted with one or more A,
- —C(O)—NRbRc, wherein Rb and Rc are each independently
- H,
- C1-7alkyl, optionally substituted with one or more halo, methyl, —(CH2)t-hydroxy, or cyano,
- —(CH2)t—C3-7cycloalkyl, optionally substituted by one or more B,
- and t is 0, 1, 2, 3, 4, 5 or 6,
- —(CH2)u—O—C1-7alkyl, wherein u is 2, 3, 4, 5 or 6,
- —CHRi—C(O)ORii, wherein Ri is H, benzyl or C1-4alkyl, and Rii is H or C1-7alkyl,
- —S(O)2—C1-7alkyl,
- —S(O)2—C3-7cycloalkyl,
- —(CH2CH2O)vRiii, wherein v is from 1 to 3, and Riii is H or C1-7alkyl,
- —(CH2)w-heteroaryl or —(CH2)w-aryl, each optionally substituted by one or more E, and wherein w is 0, 1, 2, 3, or 4,
- —(CH2)x-heterocyclyl, wherein x is 0, 1, 2, 3 or 4, and wherein heterocyclyl is optionally substituted by one or more
- oxo,
- C1-7alkyl,
- C3-7cycloalkyl, optionally substituted with one or more B,
- CN,
- benzyl, optionally substituted with one or more E,
- —(CH2)y—C(O)Riv, wherein y is 0, 1, 2, 3 or 4, and Riv is hydroxy, C1-7alkyl, or C1-7alkoxy,
- —(CH2)z—C(O)NRvRvi, —(CH2)zNRvRvi—C(O)—C1-7alkyl or —(CH2)zNRvRvi—C(O)—O—C1-7alkyl, wherein z is 0, 1, 2, 3 or 4, and Rv and Rvi are independently
- hydrogen,
- C1-7alkyl, optionally substituted by one or more halo, OH or CN,
- C3-7cycloalkyl, optionally substituted by one or more B,
- 5- or 6-membered heterocyclyl, optionally substituted by one or more A, or
- Rv and Rvi together with the nitrogen to which they are bound form a 5- or 6-membered heterocycloalkyl, optionally substituted by one or more A, or
- Rb and Rc together with the nitrogen to which they are bound form a heterocyclyl or heteroaryl moiety, optionally substituted with one or more A, or
- Rb and Rc together with the nitrogen to which they are bound form a 7- to 12-membered spirocyclic heterocycle, optionally substituted with one or more A;
- with the proviso that Rb and Rc are not simultaneously H, and at least one of R3, R5, and R6 being other than hydrogen;
- A is hydroxy, oxo, C1-7alkyl, C1-7alkoxy, C1-7haloalkyl, C1-7hydroxyalkyl, halo, or CN;
- B is halo, hydroxy, CN, C1-4alkyl, benzyloxy, or C1-4haloalkyl;
- and
- E is halo, CN, NO2, hydroxy, C1-7alkyl, C1-7alkoxy, C1-7haloalkyl, C1-7hydroxyalkyl, C1-7cyanoalkyl, C1-7haloalkoxy, or C3-7cycloalkyl;
- with the proviso that at least one of R3, R5, and R6 being other than hydrogen;
- or a pharmaceutically acceptable salt thereof.
45 more elements
Dependencies are inferred from the claim text.